Does rosuvastatin reduce ischemia/reperfusion injury in humans in-vivo? A randomized, double-blind, placebo-controlled trial.

Trial Profile

Does rosuvastatin reduce ischemia/reperfusion injury in humans in-vivo? A randomized, double-blind, placebo-controlled trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2009

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Jun 2009 Results published in Arteriosclerosis Thrombosis and Vascular Biology.
    • 22 Sep 2008 Planned end date changed from 1 Aug 2006 to 1 Aug 2007 as reported by ClinicalTrials.gov.
    • 12 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top